Rosalba Torrisi, Valentina Vaira, Laura Giordano, Bethania Fernandes, Giuseppe Saltalamacchia, Raffaella Palumbo, Carlo Carnaghi, Vera Basilico, Francesco Gentile, Giovanna Masci, Rita De Sanctis, Armando Santoro
We investigated whether we could identify a panel of miRNAs associated with response to treatment in tumor tissues of patients with Hormone Receptor-positive/HER2-negative metastatic breast cancer treated with endocrine therapy (ET) and the CDK4/6 inhibitor (CDK4/6i)i palbociclib. In total, 52 patients were evaluated, with 41 receiving treatment as the first line. The overall median PFS was 20.8 months (range 2.5-66.6). In total, 23% of patients experienced early progression (<6 months). Seven miRNAs ( miR-378e , miR-1233 , miR-99b-5p , miR-1260b , miR-448 , -miR-1252-5p , miR-324-3p , miR-1233-3p ) showed a statistically significant negative association with PFS...
January 25, 2024: International Journal of Molecular Sciences